INVESTIGADORES
KROLEWIECKI Alejandro Javier
artículos
Título:
No reduction of HCV viral load in HIV patients co-infected with HCV genotype 1 during a 30days course of nitazoxanide monotherapy.
Autor/es:
LAUFER N; ABUSAMRA L; BOLCIC F; GUN A; ROLÓN MJ; PÉREZ H; KROLEWIECKI A; SALOMÓN H; QUARLERI J; CAHN P
Revista:
ANTIVIRAL RESEARCH
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Lugar: Filadelfia; Año: 2011 vol. 92 p. 497 - 499
ISSN:
0166-3542
Resumen:
There are two new drugs approved and several in development for treatment of chronic HCV; among
them nitazoxanide (NTZ). Twelve HIV/HCV genotype 1 co-infected patients were enrolled prospectively
to receive a 30 days course of oral NTZ 500 mg bid. This therapy was well tolerated in this group of HIV
patients co-infected with HCV genotype 1. Nevertheless no changes in HCV viral load were observed during
treatment in none of the patients evaluated. This data suggests that despite the promising results
reported for HCV genotype 4 mono-infected patients, NTZ exhibit poor activity as monotherapy in
HIV/HCV co-infected patients with genotype 1.